2010
DOI: 10.1158/0008-5472.can-10-1142
|View full text |Cite
|
Sign up to set email alerts
|

Using the Transcription Factor Inhibitor of DNA Binding 1 to Selectively Target Endothelial Progenitor Cells Offers Novel Strategies to Inhibit Tumor Angiogenesis and Growth

Abstract: Tumor angiogenesis is essential for malignant growth and metastasis. Bone marrow (BM)-derived endothelial progenitor cells (EPC) contribute to angiogenesis-mediated tumor growth. EPC ablation can reduce tumor growth; however, the lack of a marker that can track EPCs from the BM to tumor neovasculature has impeded progress in understanding the molecular mechanisms underlying EPC biology. Here, we report the use of transgenic mouse and lentiviral models to monitor the BM-derived compartment of the tumor stroma; … Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
56
0

Year Published

2011
2011
2014
2014

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 54 publications
(58 citation statements)
references
References 46 publications
(71 reference statements)
2
56
0
Order By: Relevance
“…Bone marrow-derived endothelial progenitor cells (EPC) are important mediators of the angiogenic switch through the production of paracrine factors and by directly incorporating into the lumen of tumor neovasculature. Suppression of EPCs leads to a delayed angiogenic switch, which is associated with impaired tumor growth and spread (2)(3)(4). Tumor EPCs are phenotypically distinct from tumor vasculature, and other bone marrow-derived cells in the tumor microenvironment.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Bone marrow-derived endothelial progenitor cells (EPC) are important mediators of the angiogenic switch through the production of paracrine factors and by directly incorporating into the lumen of tumor neovasculature. Suppression of EPCs leads to a delayed angiogenic switch, which is associated with impaired tumor growth and spread (2)(3)(4). Tumor EPCs are phenotypically distinct from tumor vasculature, and other bone marrow-derived cells in the tumor microenvironment.…”
Section: Introductionmentioning
confidence: 99%
“…Previously, we have shown that the proximal promoter of the inhibitor of DNA binding 1 (Id1), in a retroviral context, can be used to genetically modify and deliver transgenes to EPCs in vivo (4). We also showed that Id1-marked EPCs could be tracked from the bone marrow compartment to the tumor bed, where they were eventually incorporated into the tumor vasculature.…”
Section: Introductionmentioning
confidence: 99%
“…Perhaps most importantly, future studies should also formally demonstrate that CEPs give rise to the bone marrow-derived ECs that incorporate in the tumor blood vessels. Because CEPtracing experiments (16) were not performed, the current study (12) provides only indirect evidence that the late CEP spike gives rise to the pool of bone marrow-derived ECs.…”
Section: Study Resultsmentioning
confidence: 98%
“…Upregulation of Id1 is found in several types of human cancers (Rothschild et al, 2011;Redrado et al, 2013). Id1 plays a role as promoter in several important steps during cell malignant progression, including cell proliferation (Cheng et al, 2011;Strong et al, 2013), invasiveness (Ao et al, 2012;Sun et al, 2012), angiogenesis (Mellick et al, 2010) and even associated with prognosis (Sun et al, 2012;Castañon et al, 2013). Id1 has been found to promote prostate cancer progression through various mechanisms.…”
Section: Introductionmentioning
confidence: 99%